Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Price:
55.27
USD
2.77%
Market Closed
Market Cap:
$4.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
BM |
|
Meghmani Finechem Ltd
NSE:MFL
|
IN |
|
A
|
Aether Global Innovations Corp
CNSX:AETH
|
CA |
|
N
|
NET Power Inc
NYSE:NPWR
|
US |
|
Bosch Ltd
NSE:BOSCHLTD
|
IN |
|
Takkt AG
XETRA:TTK
|
DE |
|
B
|
Biglari Holdings Inc
NYSE:BH
|
US |
|
F
|
Form Bio Co Ltd
KOSDAQ:377220
|
KR |
|
I
|
Inforich Inc
TSE:9338
|
JP |
|
Asuransi Jiwa Sinarmas MSIG Tbk PT
IDX:LIFE
|
ID |
|
Xtep International Holdings Ltd
HKEX:1368
|
CN |
|
A-Zenith Home Furnishings Co Ltd
SSE:603389
|
CN |
|
H
|
Hil Industries Bhd
KLSE:HIL
|
MY |
|
S
|
Solarvest Holdings Bhd
KLSE:SLVEST
|
MY |
|
Lite-On Technology Corp
TWSE:2301
|
TW |
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
Triangle Tyre Co Ltd
SSE:601163
|
CN |
|
Television Francaise 1 SA
PAR:TFI
|
FR |
|
Ergomed PLC
LSE:ERGO
|
UK |
Multiples-Based Value
The
Multiples-Based Value for
Kiniksa Pharmaceuticals Ltd (KNSA)
under the Base Case is
hidden
USD.
Compared with the current market price of 55.27 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
KNSA Multiples-Based Value
LOCKED
Multiples Across Competitors
KNSA Competitors Multiples
Kiniksa Pharmaceuticals Ltd Competitors
Kiniksa Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| BM |
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
4.2B USD | 6.2 | 71.5 | 48.8 | 49.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 6 | 87.3 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 4.8 | 22.8 | 16.6 | 16.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 5.6 | 19.2 | 12 | 14.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 9 | 27.2 | 20.4 | 21.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.2 | 16.5 | 11.9 | 13.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.6 | 37.4 | 40.3 | 41.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 2.7 | 29.5 | 10.1 | 12.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
